These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21779428)

  • 1. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
    Weisberg E; Roesel J; Furet P; Bold G; Imbach P; Flörsheimer A; Caravatti G; Jiang J; Manley P; Ray A; Griffin JD
    Genes Cancer; 2010 Oct; 1(10):1021-32. PubMed ID: 21779428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
    Weisberg E; Roesel J; Bold G; Furet P; Jiang J; Cools J; Wright RD; Nelson E; Barrett R; Ray A; Moreno D; Hall-Meyers E; Stone R; Galinsky I; Fox E; Gilliland G; Daley JF; Lazo-Kallanian S; Kung AL; Griffin JD
    Blood; 2008 Dec; 112(13):5161-70. PubMed ID: 18820131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of novel mutant FLT3 kinase inhibitors.
    Weisberg E; Choi HG; Barrett R; Zhou W; Zhang J; Ray A; Nelson EA; Jiang J; Moreno D; Stone R; Galinsky I; Fox E; Adamia S; Kung AL; Gray NS; Griffin JD
    Mol Cancer Ther; 2010 Sep; 9(9):2468-77. PubMed ID: 20807780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
    Weisberg E; Kung AL; Wright RD; Moreno D; Catley L; Ray A; Zawel L; Tran M; Cools J; Gilliland G; Mitsiades C; McMillin DW; Jiang J; Hall-Meyers E; Griffin JD
    Mol Cancer Ther; 2007 Jul; 6(7):1951-61. PubMed ID: 17620426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.
    Weisberg E; Barrett R; Liu Q; Stone R; Gray N; Griffin JD
    Drug Resist Updat; 2009 Jun; 12(3):81-9. PubMed ID: 19467916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.
    Hatcher JM; Weisberg E; Sim T; Stone RM; Liu S; Griffin JD; Gray NS
    ACS Med Chem Lett; 2016 May; 7(5):476-81. PubMed ID: 27190596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
    Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
    Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
    Heidel F; Solem FK; Breitenbuecher F; Lipka DB; Kasper S; Thiede MH; Brandts C; Serve H; Roesel J; Giles F; Feldman E; Ehninger G; Schiller GJ; Nimer S; Stone RM; Wang Y; Kindler T; Cohen PS; Huber C; Fischer T
    Blood; 2006 Jan; 107(1):293-300. PubMed ID: 16150941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
    Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
    Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
    Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
    EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
    Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
    Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
    Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
    Weisberg EL; Puissant A; Stone R; Sattler M; Buhrlage SJ; Yang J; Manley PW; Meng C; Buonopane M; Daley JF; Lazo S; Wright R; Weinstock DM; Christie AL; Stegmaier K; Griffin JD
    Oncotarget; 2017 Aug; 8(32):52026-52044. PubMed ID: 28881711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives.
    Sobhanifar MA; Mashkani B; Saadatmandzadeh M; Sadeghnia HR; Mousavi SH
    Biomed Pharmacother; 2018 Dec; 108():893-905. PubMed ID: 30372901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
    Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG
    Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
    Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N
    Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance in mutant FLT3-positive AML.
    Weisberg E; Sattler M; Ray A; Griffin JD
    Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.